Komori

Fiscal year ending September 2026 First-Quarter Financial Results Presentation

Results presentationFirst quarter, FY ending Sep 2026Published 2026-02-16 13:00

2026年9月期第1四半期は、売上高が前年同期より21百万円増えた一方、研究開発費などの販管費増加により営業損失は4百万円拡大した。会社は売上高・販管費とも計画どおりと説明している。

Contents of this document

Financial results presentationFirst quarter of the fiscal year ending September 202610 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥63 million
Operating profit¥-125 million
Ordinary income¥-124 million
Net income¥-125 million
Selling, general and administrative expenses¥175 million
Results for the three months of the current quarter
Net Sales¥63 million
Gross profit¥49 million
Selling, general and administrative expenses¥175 million
Operating profit-¥125 million
Ordinary income△124百万円
Quarterly net income-¥125 million
Full-year earnings forecast
Net Sales
¥1,035 million
Operating profit
¥-356 million
Ordinary income
¥175 million
Net income for the current fiscal year
¥146 million
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progressing as planned
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • 売上高の前年同期差異+¥21 million
  • 売上総利益の前年同期差異+¥28 million
  • 販管費の前年同期差異+¥32 million
  • 研究開発費の前年同期差異+¥23 million
  • 人件費の前年同期差異Up ¥4 million
  • 営業利益の前年同期差異−¥4 million
  • 経常利益の前年同期差異−¥3 million
  • 四半期純利益の前年同期差異−¥3 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
民間案件は既に契約済みまたはそれに準ずる案件のみを業績予想に織り込む方針。数値前提はNot disclosed。
New initiatives
  • 開発型バイオファウンドリから、生産機能も持つ垂直統合型バイオファウンドリへの展開
  • パイロットスケールのバイオ生産設備の整備・運用
  • 2027年の民間企業向けバイオファウンドリサービス開始を目指す展開
  • 2028年の製品販売事業開始を目指す展開
  • 国産木材由来エタノール・SAFの社会実装と、2030年の年産数万kL規模を目指す計画
Key KPIsA metric the company considers important as a management benchmark.
  • 研究員数(GE研)26 people
    Year on year against the same period last year前期比+4名
  • 研究員数(BF研)11 people
    Year on year against the same period last year前期比±0名
  • Number of employees50 people
  • Target for development and commercialization of bioproducts16以上
  • 発酵設備規模3,000 L最大
  • Productivity Improvement3 x
Segment results
Stage 2 (development stage)
Net Sales
¥63 million
Change from the year-earlier period+¥21 million
Stage 3 (commercialization stage)
Net Sales
¥0 million
Change from the year-earlier period+¥0 million
Financial targets
自己資本比率の実績は2025年12月末60.4%。財務目標はNot disclosed。
Market Size / Share
Market size and market share figures were not disclosed
Number of employees
Number of Employees50 people
内研究開発部門37 people
Capital expenditures
20億円程度(建屋・設備分)
Contents of this document
ItemDetails
Document typeFinancial results presentation
Fiscal Period CoveredFirst quarter of the fiscal year ending September 2026
Net Sales¥63 million
Operating profit¥-125 million
Ordinary income¥-124 million
Net income¥-125 million
Selling, general and administrative expenses¥175 million
Results for the three months of the current quarterNet Sales ¥63 million / Gross profit ¥49 million / Selling, general and administrative expenses ¥175 million / Operating profit -¥125 million / Ordinary income △124百万円 / Quarterly net income -¥125 million
Full-year earnings forecastNet Sales ¥1,035 million / Operating profit ¥-356 million / Ordinary income ¥175 million / Net income for the current fiscal year ¥146 million
Self-assessment against the planProgressing as planned
Segment resultsStage 2 (development stage) Net Sales ¥63 million / Profit Not disclosed / Change from the year-earlier period +¥21 million / Stage 3 (commercialization stage) Net Sales ¥0 million / Profit Not disclosed / Change from the year-earlier period +¥0 million
Breakdown of Factors Affecting the ChangeFactors 売上高の前年同期差異 / Amount +¥21 million, Factors 売上総利益の前年同期差異 / Amount +¥28 million, Factors 販管費の前年同期差異 / Amount +¥32 million, Factors 研究開発費の前年同期差異 / Amount +¥23 million, Factors 人件費の前年同期差異 / Amount Up ¥4 million, Factors 営業利益の前年同期差異 / Amount −¥4 million, Factors 経常利益の前年同期差異 / Amount −¥3 million, Factors 四半期純利益の前年同期差異 / Amount −¥3 million
Key KPIsIndicator name 研究員数(GE研) / Value 26 people / Year on year against the same period last year 前期比+4名, Indicator name 研究員数(BF研) / Value 11 people / Year on year against the same period last year 前期比±0名, Indicator name Number of employees / Value 50 people / Year on year against the same period last year Not disclosed, Indicator name Target for development and commercialization of bioproducts / Value 16以上 / Year on year against the same period last year Not disclosed, Indicator name 発酵設備規模 / Value 3,000 L(最大) / Year on year against the same period last year Not disclosed, Indicator name Productivity Improvement / Value 3 x / Year on year against the same period last year Not disclosed
Number of employeesNumber of Employees 50 people / 内研究開発部門 37 people / Changes and hiring plans during the period Not disclosed
Assumptions Underlying the Business Outlook民間案件は既に契約済みまたはそれに準ずる案件のみを業績予想に織り込む方針。数値前提はNot disclosed。
Financial targets自己資本比率の実績は2025年12月末60.4%。財務目標はNot disclosed。
Capital expenditures20億円程度(建屋・設備分)
Market Size / ShareMarket size and market share figures were not disclosed
New initiatives開発型バイオファウンドリから、生産機能も持つ垂直統合型バイオファウンドリへの展開, パイロットスケールのバイオ生産設備の整備・運用, 2027年の民間企業向けバイオファウンドリサービス開始を目指す展開, 2028年の製品販売事業開始を目指す展開, 国産木材由来エタノール・SAFの社会実装と、2030年の年産数万kL規模を目指す計画
Items this document does not state (12)
Gross Profit MarginOperating profit marginProgress against full-year forecastUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

Fiscal year ending September 2026 First-Quarter Financial Results Presentation | Green Earth Institute Co.,Ltd. (9212) timely disclosure | Komori